Mayflower Financial Advisors, LLC Viking Therapeutics, Inc. Transaction History

Mayflower Financial Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 25, 2023	BUY	$2.72 - $9.4 $36,679 - $126,759	13,485 New	13,485 $0
Q3 2022 Oct 19, 2022	BUY	$2.55 - $3.89 $34,386 - $52,456	13,485 New	13,485 $37,000
Q3 2021 Oct 26, 2021	SELL	$5.58 - $7.04 $2,790 - $3,520	-500 Reduced 3.58%	13,485 $79,000
Q2 2021 Jul 29, 2021	SELL	$5.19 - $6.73 $2,039 - $2,644	-393 Reduced 2.73%	13,985 $84,000
Q1 2021 Apr 23, 2021	SELL	$5.74 - $9.67 $8,036 - $13,538	-1,400 Reduced 8.87%	14,378 $91,000
Q4 2020 Apr 12, 2021	BUY	$5.3 - $6.71 $83,623 - $105,870	15,778 New	15,778 $89,000

474

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.18B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Mayflower Financial Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Mayflower Financial Advisors, LLC with notifications on news.